N Harbeck Selected Research

Neoadjuvant Therapy

1/2017	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
9/2011	PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

N Harbeck Research Topics

Disease

80	Breast Neoplasms (Breast Cancer) 03/2022 - 01/2000
41	Neoplasms (Cancer) 01/2022 - 01/2000
14	Neoplasm Metastasis (Metastasis) 03/2016 - 01/2000
5	Carcinoma (Carcinomatosis) 09/2003 - 01/2001
4	Pain (Aches) 04/2020 - 01/2016
3	Neutropenia 01/2018 - 09/2015
2	Arthralgia (Joint Pain) 04/2020 - 02/2014
2	Disease Progression 01/2018 - 01/2016
2	Triple Negative Breast Neoplasms 01/2017 - 12/2009
2	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2017 - 07/2007
2	Ovarian Neoplasms (Ovarian Cancer) 08/2011 - 04/2011
2	Cardiotoxicity 04/2009 - 05/2004
1	Myalgia 04/2020
1	Musculoskeletal Pain 04/2020
1	Febrile Neutropenia 09/2017
1	Residual Neoplasm 01/2017
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2017
1	Unilateral Breast Neoplasms 10/2016
1	Obesity 06/2015
1	Chronic Disease (Chronic Diseases) 02/2013

Drug/Important Bio-Agent (IBA)

18	Hormones (Hormone)IBA 12/2021 - 02/2001
15	Plasminogen Activator Inhibitor 1IBA 05/2013 - 01/2000
12	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2017 - 01/2000
8	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2000
8	Letrozole (Femara)FDA LinkGeneric 04/2020 - 12/2008
7	Trastuzumab (Herceptin)FDA Link 03/2022 - 05/2004
7	AntigensIBA 08/2011 - 01/2000
6	Progesterone Receptors (Progesterone Receptor)IBA 12/2021 - 01/2000
6	Docetaxel (Taxotere)FDA Link 09/2017 - 09/2006
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2017 - 05/2004
6	Plasminogen Activators (Plasminogen Activator)IBA 01/2017 - 07/2001
6	Epirubicin (Ellence)FDA LinkGeneric 06/2015 - 05/2004
5	Estrogen ReceptorsIBA 12/2021 - 01/2016
5	AnthracyclinesIBA 01/2013 - 12/2004
5	Proteins (Proteins, Gene)FDA Link 04/2011 - 01/2000
5	Biological FactorsIBA 10/2010 - 01/2000
4	Paclitaxel (Taxol)FDA LinkGeneric 03/2022 - 09/2011
4	Glycoproteins (Glycoprotein)IBA 09/2001 - 03/2000
3	Fulvestrant (Faslodex)FDA Link 01/2021 - 09/2009
3	Aromatase InhibitorsIBA 04/2020 - 06/2013
3	Phenobarbital (Luminal)FDA Link 06/2019 - 02/2013
3	palbociclibIBA 04/2019 - 01/2016
3	Biosimilar PharmaceuticalsIBA 01/2018 - 09/2015
3	Pharmaceutical PreparationsIBA 01/2017 - 06/2011
3	taxaneIBA 04/2016 - 01/2013
3	N,N'-bis(4-azidobenzoyl)cystineIBA 02/2016 - 10/2014
3	Darbepoetin alfa (Aranesp)FDA Link 01/2014 - 09/2011
3	Serine Proteases (Serine Protease)IBA 04/2011 - 01/2000
3	Estrogens (Estrogen)FDA Link 12/2009 - 01/2000
3	Monoclonal AntibodiesIBA 09/2001 - 02/2001
3	Messenger RNA (mRNA)IBA 02/2001 - 01/2000
2	pertuzumabIBA 03/2022 - 11/2017
2	abemaciclibIBA 01/2022 - 12/2021
2	ErbB Receptors (EGF Receptor)IBA 12/2021 - 04/2019
2	Filgrastim (Neupogen)FDA Link 01/2018 - 09/2015
2	Diphosphonates (Bisphosphonates)IBA 01/2017 - 03/2016
2	Tumor Biomarkers (Tumor Markers)IBA 01/2017 - 08/2011
2	Anastrozole (Arimidex)FDA LinkGeneric 02/2014 - 06/2013
2	Peptide Hydrolases (Proteases)FDA Link 08/2011 - 04/2011
2	Tamoxifen FDA LinkGeneric 12/2010 - 12/2008
2	Cathepsin BIBA 11/2004 - 01/2000
2	Urokinase Plasminogen Activator ReceptorsIBA 11/2004 - 10/2000
2	Taxoids (Taxanes)IBA 12/2003 - 09/2003
2	SteroidsIBA 10/2003 - 02/2001
2	Biological ProductsIBA 09/2003 - 06/2003
2	CathepsinsIBA 09/2001 - 01/2000
2	Cell Surface ReceptorsIBA 07/2001 - 06/2001
2	Plasminogen InactivatorsIBA 06/2001 - 01/2000
2	Tissue ExtractsIBA 06/2001 - 10/2000
2	RNA (Ribonucleic Acid)IBA 02/2001 - 06/2000
2	AntibodiesIBA 10/2000 - 01/2000
1	2- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamideIBA 01/2021
1	Carboplatin (JM8)FDA LinkGeneric 01/2018
1	Gemcitabine FDA Link 01/2018
1	130-nm albumin-bound paclitaxelIBA 01/2018
1	pegfilgrastim (Neulasta)FDA Link 09/2017
1	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2017
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 09/2017
1	2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA 01/2017
1	Clodronic Acid (Clodronate)IBA 03/2016
1	Zoledronic Acid (Zometa)FDA Link 03/2016
1	EnzymesIBA 08/2011
1	ImmunosorbentsIBA 08/2011
1	Tissue Kallikreins (Tissue Kallikrein)IBA 08/2011
1	Kallikreins (Kallikrein)IBA 04/2011
1	exemestane (Aromasin)FDA Link 12/2010

Therapy/Procedure

44	Therapeutics 01/2022 - 01/2000
25	Drug Therapy (Chemotherapy) 01/2018 - 01/2000
10	Adjuvant Chemotherapy 04/2016 - 01/2000
2	Precision Medicine 01/2022 - 02/2013
2	Secondary Prevention 01/2018 - 01/2018
2	Neoadjuvant Therapy 01/2017 - 09/2011
2	Adjuvant Radiotherapy 10/2016 - 11/2015
2	Radiotherapy 10/2016 - 05/2006
2	Segmental Mastectomy (Lumpectomy) 10/2016 - 11/2015
2	Combination Drug Therapy (Combination Chemotherapy) 04/2009 - 06/2001
1	Complementary Therapies (Alternative Medicine) 04/2020
1	Withholding Treatment 01/2018
1	Immunotherapy 01/2017
1	Palliative Care (Palliative Therapy) 12/2014